ITM, ANTSO extending partnership

By staff writers

December 21, 2021 -- ITM Isotope Technologies Munich SE and the Australian Nuclear Science and Technology Organization (ANTSO) are extending their partnership through a further long-term licensing agreement.

Under the terms of the agreement, ANSTO will continue producing n.c.a. Lutetium-177 for the Australian and New Zealand markets, using ITM's production technology. The aim of the partnership is to address the needs of patients, clinicians, and partners alike.

ITM also retains all intellectual property rights to the medical radioisotope. Further details of the agreement were not disclosed.

Copyright © 2021

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking